《新股消息》康诺亚生物(02162.HK)今日起招股入场费26,918.55元

AAFN2021-06-25

内地生物科技公司康诺亚生物-B(02162.HK)公布招股详情，计划发售5,826.45万股股份，当中约10%在港公开发售，招股价介乎50.5元至53.3元，每手500股，入场费26,918.55元，由今日(25日)起至下周三(30日)公开招股，预计於7月8日上市。摩根士丹利、中金及华泰国际为联席保荐人。公司专注於自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法，核心产品CM310，用於治疗多种...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2146802114?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/d17cb0ea313437e7afb8bad7f25dce9a","is_english":false,"pubTime":"2021-06-25 09:54","share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","id":"2146802114","market":"us","top_or_hot":-1,"title":"《新股消息》康诺亚生物(02162.HK)今日起招股  入场费26,918.55元","media":"AAFN","content":"<div>\n<p>内地生物科技公司康诺亚生物-B(02162.HK)公布招股详情，计划发售5,826.45万股股份，当中约10%在港公开发售，招股价介乎50.5元至53.3元，每手500股，入场费26,918.55元，由今日(25日)起至下周三(30日)公开招股，预计於7月8日上市。摩根士丹利、中金及华泰国际为联席保荐人。公司专注於自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法，核心产品CM310，用於治疗多种...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1107932&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n","source":"aastocks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《新股消息》康诺亚生物(02162.HK)今日起招股  入场费26,918.55元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《新股消息》康诺亚生物(02162.HK)今日起招股  入场费26,918.55元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:54 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1107932&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>内地生物科技公司康诺亚生物-B(02162.HK)公布招股详情，计划发售5,826.45万股股份，当中约10%在港公开发售，招股价介乎50.5元至53.3元，每手500股，入场费26,918.55元，由今日(25日)起至下周三(30日)公开招股，预计於7月8日上市。摩根士丹利、中金及华泰国际为联席保荐人。公司专注於自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法，核心产品CM310，用於治疗多种...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1107932&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1107932&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","article_id":"2146802114","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/d17cb0ea313437e7afb8bad7f25dce9a"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2146802114","pubTimestamp":1624586055,"sourceInfo":{"source_id":"aastocks","name":"阿思达克财经"},"weMediaInfo":null,"summary":"内地生物科技公司康诺亚生物-B公布招股详情，计划发售5,826.45万股股份，当中约10%在港公开发售，招股价介乎50.5元至53.3元，每手500股，入场费26,918.55元，由今日起至下周三公开招股，预计於7月8日上市。候选药物目前均处於开发阶段。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"[New share news] Connaught Bio (02162. HK) has an entrance fee of 26,918.55 yuan from today","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"内地生物科技公司康诺亚生物-B(02162.HK)公布招股详情，计划发售5,826.45万股股份，当中约10%在港公开发售，招股价介乎50.5元至53.3元，每手500股，入场费26,918.55元，由今日(25日)起至下周三(30日)公开招股，预计於7月8日上市。摩根士丹利、中金及华泰国际为联席保荐人。公司专注於自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法，核心产品CM310，用於治疗多种过敏性疾病，如中重度特应性皮炎(AD)、中重度嗜酸性哮喘和慢性鼻窦炎伴鼻息肉(CRSwNP)以及潜在慢性阻塞性肺疾病(COPD)。 除核心产品外，公司的管线还包括八种处於不同研发阶段的候选药物，其中五种为临床阶段候选药物，以及三种处於可进入临床试验申请阶段。候选药物目前均处於开发阶段。康诺亚引入达15名基石投资者，包括Invesco Ltd.、UBS Asset Management (Singapore)、Hillhouse Capital及Boyu Capital Opportunities Master Fund等，合共认购1.9亿美元股份。公司预计，以招股价中位数51.9元计，所得款项净额为28.64亿元，约60%用於核心及主要产品的研发及商业化；约15%将用於公司其他在研产品的临床前评估及临床开发；约15%支付公司新生产及研发设施的租赁付款；约10%用於公司的一般企业及营运资金用途。 (sw/u)~阿思达克财经新闻网址: www.aastocks.com","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2146802114"}

《新股消息》康诺亚生物(02162.HK)今日起招股 入场费26,918.55元

精彩评论

《新股消息》康诺亚生物(02162.HK)今日起招股入场费26,918.55元